

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Sanai Health Industry Group Company Limited (the “**Company**”) is pleased to announce that Mr. She Hao (佘昊) (“**Mr. She**”) has been appointed as an executive Director of the Company with effect from 11 November 2019.

Mr. She, aged 36, holds a bachelor degree in bioengineering from Xiang Tan University in 2005, and a master of business administration from University of Electronic Science and Technology of China in 2013. He served as a Research and Development Engineer and project supervisor in Shanghai Biolaxy Medical Science and Technology Co. Ltd.* (上海藍心醫藥科技有限公司) (a pharmaceutical Research and Development institute, which was then acquired by Anbo Biotechnology Co., Ltd.* (安博生物科技有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司)), responsible for matters relating to pharmaceutical research and development from 2006 to 2011; He served as a quality manager in Yifeng Pharmacy Chain Co., Ltd.* (益豐大藥房連鎖股份有限公司) (a pharmaceutical circulation enterprise, a company listed in Shanghai Stock Exchange, stock code: SH603939), responsible for channel construction and government relations from the end of 2013 to the end of 2014; He served as an investment manager, senior investment manager and investment director in Fortune Link Investment Holdings Limited* (東方匯富投資控股有限公司) (a private equity investment institute), responsible for investment matters relation to pharmaceuticals and other greater health projects from 2015 to 2017; He served as an investment manager in the Investment and Development Department of Jiangmen Sugarcane Chemical Factory (Group) Co., Ltd. (江門甘蔗化工廠(集團)股份有限公司, a company listed in Shenzhen Stock Exchange, stock code: SZ000576), responsible for investment matters from September 2017 to November 2019. Mr. She has extensive experience in terms of pharmaceutical research and development, circulation and pharmaceutical investment.

The Company had entered into a service contract with Mr. She for a term of 2 years, which is subject to retirement by rotation and re-election at annual general meetings in accordance with the articles of association of the Company. Mr. She is entitled to receive a Director's fee of HK\$20,000 per month as an executive Director of the Company with discretionary bonus, subject to the Company's performance and his individual contribution. The remuneration was determined by reference to his experience, duties and responsibilities, the prevailing market conditions and the recommendation from the remuneration committee of the Company. The Company may also pay additional fees to Mr. She based on his time, efforts and expertise to be exercised on Company affairs as determined by the Board.

Save as disclosed above, as at the date of this announcement, Mr. She (i) did not hold any other major appointment and professional qualification nor directorships in any public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (ii) does not have any relationship with any Directors, senior management, substantial nor controlling shareholders (having the meaning ascribed to them in the Listing Rules) of the Company; (iii) does not hold any position with the Company nor other members of the Group; and (iv) does not have any interest in nor is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information which is discloseable pursuant to any requirements set out in Rules 13.51(2) (h) to (v) of the Listing Rules, and there are no other matters that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to extend a warm welcome to Mr. She for joining the Board.

By order of the Board
Sanai Health Industry Group Company Limited
Chen Chengqing
Chairman

Hong Kong, 11 November 2019

As at the date of this announcement (subsequent to the above changes), the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Mr. Tu Fangkui, Mr. Wang Zihao, and Mr. Long Jun.

* *For identification purpose only*